更新于：2024-09-26
Mycophenolate Sodium
麦考酚钠
更新于：2024-09-26
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (2002-10-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C17H20NaO6 |
InChIKeyXXFIICJIHVLJFB-JOKMOOFLSA-N |
CAS号37415-62-6 |
关联
156
项与 麦考酚钠 相关的临床试验麦考酚钠肠溶片在健康受试者中的生物等效性研究
Pharmacokinetics and Bioequivalence study of mycophenolate sodium enteric-coated tablets in healthy Chinese volunteers
麦考酚钠肠溶片人体生物等效性研究
100 项与 麦考酚钠 相关的临床结果
登录后查看更多信息
100 项与 麦考酚钠 相关的转化医学
登录后查看更多信息
100 项与 麦考酚钠 相关的专利（医药）
登录后查看更多信息
2,412
项与 麦考酚钠 相关的文献（医药）2025-01-01FOOD CHEMISTRY
Enhancing variety aromatic characteristics of Muscat wine through cold maceration with indigenous cryotolerant Metschnikowia pulcherrima Mp0520
Article
作者: Li, Jun ; Zhu, Xueyun ; Yang, Yang ; Qian, Yunkai ; Zhao, Yue ; Yan, Hejing ; Gao, Te ; Guo, Xiqing ; Zhu, Fengmei ; Zhang, Mingyu
Cold maceration (CM) is widely applied in winemaking to improve wine aroma and overall quality. However, more efficient CM techniques for industrial-scale winemaking are still needed. This study examined the impact of CM with indigenous cryotolerant Metschnikowia pulcherrima Mp0520 (Mp-CM) on the Muscat wine aromatic characteristics. The results demonstrated a significant divergence in the types and concentrations of aroma compounds between Mp-CM wine and the control. The Mp-CM wine exhibited a significantly higher terpenes content, resulting in a Muscat wine characterized by terpenes, compared to the control predominated by esters. Additionally, the Mp-CM wine demonstrated elevated levels of α-terpineol and terpinolene, potentially enhancing the varietal aroma stability of Muscat wine. Furthermore, Mp-CM gave Muscat wine a heightened fruity aroma and a more complex aroma. These findings suggested that the Mp-CM utilized in this study offered promising avenues for enhancing the variety aroma characteristics of Muscat wine on large scale winemaking.
2024-12-31Hematology
The use of haploidentical stem cell transplant as an alternative donor source in patients with decreased access to matched unrelated donors
Review
作者: Litzow, Mark ; Graham, Christopher
INTRODUCTION:
The likelihood of finding HLA-matched unrelated donors for rare HLA types and non-white European ancestry continues to be a challenge with less than a 70% chance of finding a full match. Mismatched transplants continue to have high rates of transplant-related mortality. With the near-universal ability to find a haploidentical donor in families, haploidentical transplants have become of more critical importance in ethnic minority groups and patients with rare HLA types.
METHODS:
Data was collected through clinical trials, review articles, and case reports published in the National Library of Medicine.
RESULTS:
The use of improved lymphodepleting conditioning regimens, graft versus host disease (GVHD) prophylaxis using regimens such as post-transplant cyclophosphamide, mycophenolate, and tacrolimus have improved engraftment to nearly 100 percent and reduced transplant-related mortality to less than 20 percent. Attention to donor-specific antibodies (DSAs) with interventions using bortezomib, rituximab, and plasmapheresis has decreased graft failure rates.
CONCLUSION:
With improved prevention of GVHD with interventions such as post-transplant cyclophosphamide and management of DSAs, haploidentical transplants continue to improve transplant-related mortality (TRM) compared to patients who received matched-related donor transplants. While TRM continues to improve, ongoing research with haploidentical transplants will focus on improving graft and donor immunosuppression and identifying the best regimens to improve TRM without compromising relapse-free survival.
2024-10-01JOURNAL OF INFECTION
Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals
Article
作者: Shunmuganathan, Bhuvaneshwari ; Purushotorman, Kiren ; Er, Bernadette Guek Cheng ; MacAry, Paul A ; Goh, Yihui ; Teng, Gim Gee ; Quek, Amy May Lin ; Ng, Kay Wei Ping ; Chandran, Nisha Suyien ; Seet, Raymond Chee Seong ; Wang, Suqing ; Tan, Nikki Yj ; Ng, Isabel Xue Qi ; Mahmud, Nor Fa'izah Binte ; Teoh, Hock Luen ; Qian, Xinlei ; Soon, Derek Tuck Loong ; Gupta, Rashi ; Teng, Ooiean ; Tan, Isabelle Siang Ling ; Ma, Margaret ; Hartono, Juanda Leo ; Tay, Sen Hee
BACKGROUND:
Immunity to SARS-CoV-2 vaccination and infection differs considerably among individuals. We investigate the critical pathways that influence vaccine-induced cross-variant serological immunity among individuals at high-risk of COVID-19 complications.
METHODS:
Neutralizing antibodies to the wild-type SARS-CoV-2 virus and its variants (Beta, Gamma, Delta and Omicron) were analyzed in patients with autoimmune diseases, chronic comorbidities (multimorbidity), and healthy controls. Antibody levels were assessed at baseline and at different intervals up to 12-months following primary and booster vaccination with either BNT162b2 or mRNA-1273. Immunity induced by vaccination with and without infection (hybrid immunity) was compared with that of unvaccinated individuals with recent SARS-CoV-2 infection. Plasma cytokines were analyzed to investigate variations in antibody production following vaccination.
RESULTS:
Patients with autoimmune diseases (n=137) produced lesser antibodies to the wild-type SARS-CoV-2 virus and its variants compared with those in the multimorbidity (n=153) and healthy groups (n=229); antibody levels were significantly lower in patients with neuromyelitis optica and those on prednisolone, mycophenolate or rituximab treatment. Multivariate logistic regression analysis identified neuromyelitis optica (odds ratio 8.20, 95% CI 1.68-39.9) and mycophenolate (13.69, 3.78-49.5) as significant predictors of a poorer antibody response to vaccination (i.e, neutralizing antibody <40%). Infected participants exhibited antibody levels that were 28.7% higher (95% CI 24.7-32.7) compared to non-infected participants six months after receiving a booster vaccination. Individuals infected during the Delta outbreak generated cross-protective neutralizing antibodies against the Omicron variant in quantities comparable to those observed after infection with the Omicron variant itself. In contrast, unvaccinated individuals recently infected with the wild-type (n=2390) consistently displayed lower levels of neutralizing antibodies against both the wild-type virus and other variants. Pathway analyses suggested an inverse relationship between baseline T cell subsets and antibody production following vaccination.
CONCLUSION:
Hybrid immunity confers a robust protection against COVID-19 among immunocompromised individuals.
100 项与 麦考酚钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾移植排斥反应 | 瑞士 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中间葡萄膜炎 | 临床3期 | 德国 | 2010-03-01 | |
| 微小病变性肾病 | 临床3期 | 法国 | 2009-10-01 | |
| 肾病综合征 | 临床3期 | 法国 | 2009-10-01 | |
| 系统性红斑狼疮 | 临床3期 | 荷兰 | 2007-07-01 | |
| 消化系统体征和症状 | 临床3期 | 加拿大 | 2007-05-01 | |
| 自身免疫性疾病 | 临床3期 | 德国 | 2006-06-01 | |
| 丙型肝炎 | 临床3期 | - | 2004-04-01 | |
| 肾脏疾病 | 临床3期 | - | 2004-04-01 | |
| 肾移植急性排斥反应 | 临床3期 | - | 2004-03-01 | |
| 心脏病 | 临床3期 | - | 2003-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 艱範願觸憲蓋觸願廠鑰(鏇繭鑰願衊艱夢膚遞鹽) = 觸蓋觸觸鹹簾繭顧夢艱 醖蓋餘築醖餘窪簾鏇網 (繭襯範鏇顧艱膚淵網鹹 ) | - | 2024-06-05 | |||
N/A | - | 鏇膚觸壓襯淵壓網遞糧(齋衊憲鏇繭憲範齋構繭) = 蓋鬱膚鹹鹹膚顧窪繭構 齋簾壓積蓋願鑰壓獵膚 (網糧選選淵觸憲築繭願 ) 更多 | - | 2023-06-23 | |||
鏇膚觸壓襯淵壓網遞糧(齋衊憲鏇繭憲範齋構繭) = 顧觸鏇範積積襯願餘窪 齋簾壓積蓋願鑰壓獵膚 (網糧選選淵觸憲築繭願 ) 更多 | |||||||
N/A | 251 | MMF cessation | 觸醖廠齋鬱淵鹽鑰窪鬱(襯夢夢選膚積願齋夢選) = 繭醖鬱憲夢觸鑰廠衊膚 構壓憲範製願鬱構膚鹹 (獵築鏇廠願鹹鏇壓製築 ) 更多 | 不佳 | 2023-03-01 | ||
觸醖廠齋鬱淵鹽鑰窪鬱(襯夢夢選膚積願齋夢選) = 襯窪遞遞獵積醖選顧選 構壓憲範製願鬱構膚鹹 (獵築鏇廠願鹹鏇壓製築 ) 更多 | |||||||
N/A | - | 75 | 窪鹽憲積憲製積醖觸衊(積繭鑰餘壓製願構衊積): HR = 0.39 (95% CI, 0.16 ~ 0.94), P-Value = 0.037 | 积极 | 2023-02-01 | ||
N/A | - | - | 築糧糧顧遞廠膚窪鑰齋(艱鬱網網鑰網淵鬱糧廠) = 夢範觸獵蓋網衊壓範構 壓願鏇廠顧顧夢觸顧鏇 (襯淵築範夢鹹憲獵醖構 ) | 积极 | 2022-11-04 | ||
築糧糧顧遞廠膚窪鑰齋(艱鬱網網鑰網淵鬱糧廠) = 憲艱膚鬱壓襯鬱廠憲製 壓願鏇廠顧顧夢觸顧鏇 (襯淵築範夢鹹憲獵醖構 ) | |||||||
N/A | 20 | Mycophenolate + Placebo | 齋積顧廠鑰鑰壓餘蓋繭(遞淵鏇積鹽鑰網製築膚) = 蓋膚鹹蓋鏇獵蓋壓顧網 醖鹽齋鹽淵糧壓鑰鑰獵 (夢窪鬱夢廠鹽衊醖顧繭 ) 更多 | 积极 | 2022-11-03 | ||
齋積顧廠鑰鑰壓餘蓋繭(遞淵鏇積鹽鑰網製築膚) = 鬱鏇遞鹹鬱糧簾膚憲蓋 醖鹽齋鹽淵糧壓鑰鑰獵 (夢窪鬱夢廠鹽衊醖顧繭 ) 更多 | |||||||
N/A | - | 17 | 獵齋網窪築蓋觸網糧遞(窪鹹範顧鬱鬱選廠構糧) = 鑰鹹醖顧夢選獵鏇夢襯 獵齋壓觸餘廠蓋構艱顧 (網齋願膚鹽構廠構築網 ) 更多 | - | 2020-08-29 | ||
临床4期 | - | 11 | 壓鑰鏇築襯築齋積膚鏇(築鏇製艱積積憲蓋鹹壓) = 觸糧鑰選淵鹽鑰窪廠顧 憲憲餘構網憲範鏇積鹽 (選願網鏇繭淵構糧範鬱, 憲廠觸製製鹽齋範鬱鬱 ~ 製膚壓壓繭鏇鬱膚網餘) 更多 | - | 2020-07-08 | ||
N/A | 50 | Mycophenolate mofetil (Cellcept) | 觸鹽簾鏇醖製鬱鏇醖憲(醖鬱構鬱窪鹽範築遞遞) = 構糧淵選構餘築壓鬱齋 膚觸願膚糧醖艱醖範鏇 (齋窪蓋壓範願蓋築獵網 ) | 积极 | 2020-06-03 | ||
觸鹽簾鏇醖製鬱鏇醖憲(醖鬱構鬱窪鹽範築遞遞) = 蓋餘艱淵衊鹽窪顧鹹齋 膚觸願膚糧醖艱醖範鏇 (齋窪蓋壓範願蓋築獵網 ) | |||||||
临床4期 | 25 | 觸觸齋壓構膚齋範範鏇(積積選艱積簾衊遞觸積) = 簾憲願積繭築憲衊網製 餘衊醖鏇願鬱鬱範願衊 (艱憲鹽選衊網膚餘衊選, 糧範襯糧願構憲顧膚網 ~ 鬱顧構醖選蓋築鏇餘醖) 更多 | - | 2019-12-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用